Ibuprofen vs Paracetamol: When to Choose Which
TL;DR
- Ibuprofen (an NSAID) reduces both pain and inflammation; paracetamol (acetaminophen) relieves pain and fever but has minimal anti-inflammatory activity.
- At standard over-the-counter doses, both drugs show comparable antipyretic and analgesic efficacy for most mild-to-moderate pain and fever scenarios — but they diverge sharply in their risk profiles [5] [6].
- Choosing the safer painkiller depends on the individual: paracetamol is generally preferred in patients with gastrointestinal risk, while ibuprofen may be preferred when inflammation is a key driver. Neither drug is risk-free, and both carry dose-dependent toxicity.
Understanding Ibuprofen vs Paracetamol: Mechanisms of Action
The ibuprofen vs paracetamol debate begins at the molecular level. Although both drugs sit in the same pharmacy aisle and are often used interchangeably by the public, they work through fundamentally different pathways.
Ibuprofen is a non-selective cyclooxygenase (COX) inhibitor belonging to the propionic acid class of non-steroidal anti-inflammatory drugs (NSAIDs). It blocks both COX-1 and COX-2 enzymes, thereby reducing the synthesis of prostaglandins — lipid mediators that drive inflammation, pain sensitization, and thermoregulation. Because prostaglandins also maintain the gastric mucosal barrier, promote renal blood flow, and support platelet aggregation, COX inhibition explains both the therapeutic benefits and the well-known adverse-effect profile of ibuprofen [VERIFY].
Paracetamol (known as acetaminophen in North America — INN: paracetamol) has a mechanism that remains incompletely understood despite more than a century of clinical use. The prevailing hypothesis is that it acts primarily within the central nervous system, possibly through inhibition of a COX-3 isoform or through modulation of the endocannabinoid and serotonergic descending pain pathways. Critically, paracetamol has negligible peripheral anti-inflammatory activity, which means it will reduce pain perception and fever but will not meaningfully decrease tissue swelling, redness, or inflammatory exudate [VERIFY].
This mechanistic distinction is clinically decisive. For conditions driven predominantly by peripheral inflammation — such as acute musculoskeletal sprains, post-surgical tissue edema, or active inflammatory arthropathies — ibuprofen's COX-mediated anti-inflammatory action provides a pharmacological advantage. For simple fever or headache where inflammation is not the primary problem, paracetamol delivers comparable symptom relief with a different (and for many patients, more favorable) risk profile [1] [6].
Head-to-Head Efficacy: Ibuprofen vs Acetaminophen in Clinical Trials
A recurring question in both clinical practice and public health is whether one agent is measurably more effective than the other. The evidence is nuanced and context-dependent.
Fever
A 2023 emergency department study by Franceschi et al. evaluated paracetamol 1,000 mg alone versus a fixed-dose combination of paracetamol 500 mg plus ibuprofen 150 mg in 324 adult patients presenting with fever of bacterial, viral, or neoplastic/inflammatory origin. While no patient was treated with ibuprofen monotherapy in this cohort (reflecting standard Italian ED practice), the combination group showed outcomes that suggest additive benefit when an inflammatory component accompanies the fever [1].
In pediatrics, a 2020 JAMA Network Open systematic review and meta-analysis by Tan et al. compared acetaminophen with ibuprofen specifically in children younger than 2 years. Pooling data across multiple randomized controlled trials, the authors found that ibuprofen was at least as effective as acetaminophen for fever reduction within the first 4 hours, with some analyses favoring ibuprofen modestly. Both medications were well tolerated at standard doses [5].
A 2021 narrative review by Paul and Walson synthesized data from randomized blinded studies in children and concluded that at physician-directed dosing (paracetamol 15 mg/kg versus ibuprofen 10 mg/kg), no significant differences in antipyretic effect were observed from 0–6 hours or across 24–48 hours with single or multiple doses. When over-the-counter doses were compared (which can be lower than physician-directed doses), six of fourteen comparisons favored ibuprofen, seven showed no difference, and one favored paracetamol [6].
Pain
In a large Italian survey of 929 pediatricians managing over 6,300 cases of acute pain in children aged 7–12 years, ibuprofen was the most commonly selected first-line non-opioid analgesic (53.3% of cases), followed by acetaminophen (44.4%). This prescribing pattern reflects a perceived analgesic advantage of ibuprofen in conditions involving musculoskeletal/post-traumatic pain, earache, and sore throat, all of which carry a significant inflammatory component [3].
For postoperative analgesia, both agents are routinely used as part of multimodal regimens. In the AnAnkle randomized trial, all patients undergoing acute ankle fracture surgery received scheduled paracetamol and ibuprofen alongside patient-controlled morphine, reflecting current best practice of combining both drugs for opioid-sparing benefit [2]. Similarly, post-cesarean protocols in the trial by Carvalho et al. used scheduled acetaminophen and ibuprofen as the baseline analgesic framework, with opioids reserved for breakthrough pain [4].
Osteoarthritis and Back Pain
A 2024 systematic review and meta-analysis by Cao et al. evaluated paracetamol combination therapy in osteoarthritis and low back pain. Adding paracetamol to an NSAID such as ibuprofen produced a modest additional pain reduction at immediate-term follow-up in low back pain (mean difference −6.2 points on a 100-point scale versus ibuprofen alone; moderate-quality evidence). In osteoarthritis, the combination of paracetamol plus an NSAID also showed benefit over NSAID monotherapy, though effect sizes were small [8].
This finding underscores a practical principle: the two drugs are not truly interchangeable but complementary, acting through different pathways to produce additive analgesia.
Dosing Comparison: Ibuprofen vs Paracetamol
| Parameter | Ibuprofen | Paracetamol (Acetaminophen) |
|---|---|---|
| Drug class | NSAID (propionic acid derivative) | Para-aminophenol derivative (aniline analgesic) |
| Standard adult OTC dose | 200–400 mg every 4–6 hours | 500–1,000 mg every 4–6 hours |
| Maximum adult daily dose (OTC) | 1,200 mg/day | 4,000 mg/day (many guidelines now recommend ≤3,000 mg/day for chronic use or hepatic risk) |
| Maximum adult daily dose (Rx) | 2,400–3,200 mg/day (under medical supervision) | 4,000 mg/day |
| Pediatric dose | 5–10 mg/kg every 6–8 hours | 10–15 mg/kg every 4–6 hours |
| Onset of action | 20–30 minutes | 30–60 minutes |
| Duration of action | 4–6 hours | 4–6 hours |
| Anti-inflammatory effect | Yes (peripheral COX-1/COX-2 inhibition) | No (negligible peripheral anti-inflammatory activity) |
| Antipyretic effect | Yes | Yes |
| Available forms | Tablets, capsules, suspension, topical gel, IV (hospital) | Tablets, capsules, suspension, suppositories, IV (hospital) |
| Take with food? | Recommended (reduces GI irritation) | Not required |
Dosing notes: The Italian pediatric survey found non-recommended dosages were prescribed in only 5.3% of acetaminophen-treated cases and 4.9% of ibuprofen-treated cases, suggesting that both drugs have well-established and generally followed weight-based pediatric dosing [3]. In neonatal medicine, Kumar et al. demonstrated that oral paracetamol was non-inferior to oral ibuprofen for closure of hemodynamically significant patent ductus arteriosus in preterm neonates, with comparable adverse event profiles — though these are specialized hospital doses not applicable to general analgesic use [7].
Gastrointestinal, Hepatic, and Renal Risks
This is where the ibuprofen vs paracetamol comparison becomes most consequential for clinical decision-making.
Gastrointestinal risk: Ibuprofen's Achilles' heel
Ibuprofen, like all non-selective NSAIDs, impairs the prostaglandin-dependent gastric mucosal defense. Short-term use at OTC doses carries a relatively low absolute risk of serious GI events, but the risk increases substantially with higher doses, prolonged use, concurrent corticosteroid or anticoagulant therapy, age over 65, and a history of peptic ulcer disease. The FDA label for ibuprofen carries a boxed warning regarding serious gastrointestinal events including bleeding, ulceration, and perforation [VERIFY].
Paracetamol, by contrast, has no meaningful effect on the gastric mucosa and is the preferred analgesic/antipyretic in patients with a history of peptic ulcer disease, GI bleeding, or concurrent anticoagulation. For patients asking about the safer painkiller for the stomach, the answer is unambiguously paracetamol.
Hepatic risk: Paracetamol's critical vulnerability
Paracetamol is metabolized primarily by hepatic glucuronidation and sulfation. A small fraction is oxidized by CYP2E1 to the reactive metabolite N-acetyl-p-benzoquinone imine (NAPQI), which is normally detoxified by glutathione conjugation. When paracetamol doses exceed the liver's conjugation capacity — through acute overdose (>150 mg/kg in a single ingestion) or through chronic excessive dosing, particularly in the context of alcohol use, malnutrition, or concurrent CYP2E1 inducers — NAPQI accumulates and causes direct hepatocellular necrosis. Paracetamol overdose remains the leading cause of acute liver failure in the United States and United Kingdom [VERIFY].
Ibuprofen can cause idiosyncratic hepatotoxicity, but this is rare (estimated at fewer than 1–10 per 100,000 patient-years), and dose-dependent liver injury is not a prominent feature of the drug's profile [VERIFY].
Renal risk
Both drugs carry renal considerations. Ibuprofen reduces renal prostaglandin synthesis, which can impair renal perfusion in volume-depleted states, chronic kidney disease, heart failure, or concurrent use of ACE inhibitors/ARBs/diuretics. The risk is clinically significant and a primary reason NSAIDs are avoided in patients with eGFR < 30 mL/min [VERIFY].
Paracetamol is generally considered safer for the kidneys at therapeutic doses, though very high chronic exposure has been associated with analgesic nephropathy (historically, primarily with combination analgesics containing phenacetin). The Tan et al. meta-analysis in children under 2 years included kidney impairment as a safety outcome and found no significant signal for either drug at standard doses [5].
Cardiovascular risk
All NSAIDs, including ibuprofen, carry an FDA boxed warning for increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke. This risk may increase with duration of use and pre-existing cardiovascular disease. Naproxen may carry a lower cardiovascular risk than ibuprofen among NSAIDs, though the evidence remains debated [VERIFY].
Paracetamol at standard doses is not associated with increased cardiovascular thrombotic risk and is therefore preferred in patients with established cardiovascular disease when an analgesic or antipyretic is needed.
Adverse Effects Summary: Paracetamol vs Ibuprofen
| Adverse Effect | Ibuprofen | Paracetamol | Recommended Action |
|---|---|---|---|
| Dyspepsia / GI discomfort | Common (10–20%) | Uncommon | Take ibuprofen with food; consider switching to paracetamol or adding a PPI |
| GI ulceration / bleeding | Dose- and duration-dependent; higher in elderly, prior ulcer history | Very rare at therapeutic doses | Avoid ibuprofen in high-risk patients; use lowest effective dose for shortest duration |
| Hepatotoxicity | Rare (idiosyncratic) | Dose-dependent (>4 g/day or less with alcohol/fasting) | Never exceed recommended paracetamol dose; avoid with heavy alcohol use; N-acetylcysteine is the specific antidote for overdose |
| Acute kidney injury | Risk in dehydration, CKD, heart failure, or concurrent nephrotoxic drugs | Low risk at therapeutic doses | Ensure hydration; avoid ibuprofen in eGFR < 30; monitor renal function if prolonged use |
| Cardiovascular events (MI, stroke) | Increased risk (FDA boxed warning) | Not associated at standard doses | Avoid prolonged NSAID use in cardiovascular disease; prefer paracetamol or naproxen |
| Platelet inhibition / bleeding risk | Yes (reversible COX-1 inhibition) | No significant antiplatelet effect | Avoid ibuprofen peri-operatively or with anticoagulants when possible |
| Allergic / hypersensitivity reactions | Uncommon; cross-reactivity with aspirin in NSAID-exacerbated respiratory disease | Rare | Absolute contraindication in known NSAID-hypersensitive patients |
| Asthma exacerbation | Possible in aspirin-sensitive asthma (Samter triad) | Generally safe | Screen for aspirin sensitivity before recommending ibuprofen in asthmatics |
Special Populations: Pregnancy, Breastfeeding, Children, and the Elderly
Pregnancy
The choice between ibuprofen and paracetamol in pregnancy is governed by strong guideline consensus:
-
Paracetamol has historically been the preferred analgesic/antipyretic throughout pregnancy. Although recent observational studies have raised questions about potential associations with neurodevelopmental outcomes in offspring, major bodies including ACOG (American College of Obstetricians and Gynecologists) and the FDA continue to consider paracetamol appropriate for short-term use at the lowest effective dose when clinically indicated [VERIFY].
-
Ibuprofen is contraindicated after 20 weeks of gestation per an updated 2020 FDA Drug Safety Communication, which warned that NSAID use at 20 weeks or later can cause fetal renal dysfunction leading to low amniotic fluid (oligohydramnios) and, in the third trimester, premature closure of the ductus arteriosus. Before 20 weeks, short-term ibuprofen use may be considered on a case-by-case basis, but paracetamol remains preferred [VERIFY].
Breastfeeding
Both ibuprofen and paracetamol are considered compatible with breastfeeding by the AAP (American Academy of Pediatrics) and LactMed. Both transfer into breast milk in very low concentrations. Post-cesarean studies routinely employ both agents as scheduled baseline analgesia in breastfeeding mothers [2] [4].
Children
Both drugs are approved for use in infants from 2–3 months of age (depending on jurisdiction) for fever and mild-to-moderate pain. The systematic review by Tan et al. confirmed comparable efficacy and safety in children younger than 2 years, with ibuprofen showing slightly superior antipyretic effect in some analyses [5]. The Paul and Walson review found similar tolerability at physician-directed doses [6]. Italian pediatricians surveyed by Marseglia et al. showed a slight preference for ibuprofen in musculoskeletal and ear pain but used acetaminophen nearly as frequently [3].
Alternating or combining ibuprofen and paracetamol in children with persistent fever is a common but debated practice. Some studies suggest superior fever control with alternating therapy, but guidelines from NICE (National Institute for Health and Care Excellence) recommend considering alternating only if the child does not respond to a single agent, and caution against the practice due to increased risk of dosing errors [VERIFY]. The narrative review by Paul and Walson noted that efficacy favored combination over individual agents in 3 of 4 studies, though alternating-use results were mixed [6].
Elderly patients
The elderly are disproportionately affected by NSAID-related adverse events — GI bleeding, renal impairment, cardiovascular events, and drug interactions all increase with age and polypharmacy. The American Geriatrics Society Beers Criteria recommend avoiding chronic NSAID use in older adults [VERIFY]. Paracetamol is generally the first-line analgesic in this population, provided the total daily dose accounts for any hepatic impairment or alcohol use.
Patients on anticoagulants
Ibuprofen increases bleeding risk through both GI mucosal damage and reversible platelet inhibition. Furthermore, ibuprofen can interfere with the cardioprotective antiplatelet effect of low-dose aspirin by competing for the COX-1 binding site. The FDA recommends that patients taking aspirin for cardiovascular protection take ibuprofen at least 8 hours before or 30 minutes after immediate-release aspirin [VERIFY]. Paracetamol does not have these interactions and is the safer painkiller choice in anticoagulated patients.
Drug Interactions
Both agents participate in clinically important drug interactions, though ibuprofen's interaction profile is considerably broader:
Ibuprofen interactions of note:
- Anticoagulants (warfarin, DOACs): increased bleeding risk
- Low-dose aspirin: may block cardioprotective effect
- ACE inhibitors, ARBs, diuretics: reduced antihypertensive efficacy, increased renal risk (the "triple whammy")
- Lithium: increased lithium levels (reduced renal clearance)
- Methotrexate: increased methotrexate toxicity (reduced renal clearance)
- SSRIs/SNRIs: additive GI bleeding risk
- Corticosteroids: additive GI ulceration risk
Paracetamol interactions of note:
- Warfarin: may potentiate INR at doses > 2 g/day with regular use (monitor INR)
- Alcohol (chronic use): increased hepatotoxicity risk via CYP2E1 induction
- Isoniazid, carbamazepine, phenytoin, rifampicin: CYP2E1 inducers that may increase NAPQI production
- Combination products: patients frequently ingest paracetamol from multiple sources (cold/flu remedies, prescription opioid combinations) without realizing it, leading to accidental overdose
FAQ
Q1: Can I take ibuprofen and paracetamol together? A1: Yes. Taking ibuprofen and paracetamol simultaneously is safe in adults and is widely used in clinical practice for additive pain relief. A 2024 meta-analysis found that the combination of paracetamol plus ibuprofen provided modestly greater pain reduction than ibuprofen alone in low back pain [8]. Post-surgical protocols routinely schedule both drugs together as baseline analgesia [2] [4]. In children, combined or alternating regimens may provide superior fever control, but should generally be reserved for cases not responding to monotherapy, to reduce the risk of dosing errors [6].
Q2: Which is the safer painkiller for long-term use? A2: Neither drug is ideal for long-term use without medical supervision. For patients requiring regular analgesia over weeks to months, paracetamol at doses ≤3 g/day is generally considered the safer first-line option, provided liver function is normal and alcohol use is moderate or absent. Long-term ibuprofen use raises cumulative risks of GI bleeding, cardiovascular events, and renal impairment. If an NSAID is needed chronically, the lowest effective dose should be used for the shortest duration, often with a proton pump inhibitor for GI protection [VERIFY].
Q3: Is ibuprofen or paracetamol better for children's fever? A3: At recommended weight-based doses, both are effective and well-tolerated antipyretics in children. A systematic review of children under 2 years found comparable efficacy with a possible slight edge for ibuprofen in fever reduction within the first 4 hours [5]. A narrative review of blinded RCTs found no significant difference at physician-directed dosing [6]. The choice may depend on the clinical context: ibuprofen may be preferred when inflammation accompanies fever (e.g., otitis media), while paracetamol may be preferred in dehydrated children or those with renal concerns.
Q4: Can I take ibuprofen during pregnancy? A4: Ibuprofen is contraindicated after 20 weeks of gestation due to the risk of fetal renal dysfunction and premature ductus arteriosus closure (FDA Drug Safety Communication, 2020). Before 20 weeks, short-term use may be considered in specific circumstances, but paracetamol remains the analgesic of choice throughout pregnancy per ACOG and WHO guidance [VERIFY].
Q5: Why do some hospitals give both paracetamol and ibuprofen after surgery? A5: Multimodal analgesia — combining drugs with different mechanisms — is a cornerstone of modern postoperative pain management. Scheduled paracetamol and ibuprofen together reduce opioid requirements, which in turn reduces opioid-related side effects such as nausea, sedation, and respiratory depression. Both the AnAnkle trial in ankle fracture surgery [2] and the post-cesarean trial by Carvalho et al. [4] used this dual baseline approach, reflecting guideline recommendations from bodies including the WHO analgesic ladder and ERAS (Enhanced Recovery After Surgery) protocols.
References
[1] Franceschi F, Saviano A, Carnicelli A et al. European Review for Medical and Pharmacological Sciences 2023. PMID:37606145. pubmed.ncbi.nlm.nih.gov/37606145
[2] Sort R, Brorson S, Gögenur I. British Journal of Anaesthesia 2021. PMID:33546844. pubmed.ncbi.nlm.nih.gov/33546844
[3] Marseglia GL, Alessio M, Da Dalt L et al. Italian Journal of Pediatrics 2019. PMID:31796092. pubmed.ncbi.nlm.nih.gov/31796092
[4] Carvalho B, Sutton CD, Kowalczyk JJ et al. Regional Anesthesia and Pain Medicine 2019. PMID:30867278. pubmed.ncbi.nlm.nih.gov/30867278
[5] Tan E, Braithwaite I, McKinlay CJD et al. JAMA Network Open 2020. PMID:33125495. pubmed.ncbi.nlm.nih.gov/33125495
[6] Paul IM, Walson PD. Current Medical Research and Opinion 2021. PMID:33966545. pubmed.ncbi.nlm.nih.gov/33966545
[7] Kumar A, Gosavi RS, Sundaram V et al. The Journal of Pediatrics 2020. PMID:32336479. pubmed.ncbi.nlm.nih.gov/32336479
[8] Cao Z, Han K, Lu H et al. Drugs 2024. PMID:38937394. pubmed.ncbi.nlm.nih.gov/38937394
About the author
Dr. Stanislav Ozarchuk, PharmD, has 15 years of clinical pharmacy experience. He writes for PillsCard.com, the international drug encyclopedia.
Medical disclaimer
The information provided here is for educational purposes only and is not a substitute for professional medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication.